Three major pharmaceutical companies, AstraZeneca, Boehringer, and GSK, have agreed to cap the price of asthma inhalers at $35, effective June 1. This decision came after pressure from Democratic lawmakers to lower inhaler prices due to high costs. The companies are also focusing on making respiratory medications more accessible to uninsured and underinsured patients. The caps will apply to various respiratory products, not just inhalers. Lawmakers and organizations like KFF have highlighted the issue of high drug costs, leading pharmaceutical companies to take action and address the affordability of essential medications like asthma inhalers.
Source link
Major pharmaceutical companies put $35 monthly price cap on asthma inhalers
